It is planned to compare the efficacy and safety of cefdinir and cefdinir/clavulanic acide treatments in acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumoniae (CAP) patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
Cefdinir is used as comparator
Erzincan University Mengücek Gazi Training and Research Hospital
Erzincan, Turkey (Türkiye)
RECRUITINGYedikule Chest Diseases Training and Research Hospital
Istanbul, Turkey (Türkiye)
RECRUITINGThe comparison of clinical success rates according to laboratory parameters
Time frame: 7-10 days
The comparison of remission or relief of inflammation according to laboratory parameters
Time frame: 7-10 days
The comparison of patient satisfaction according to satisfaction questionnaire
Time frame: 7-10 days
The comparison of adverse events
Time frame: 7-10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.